IQVIA Holdings Inc. $IQV Holdings Raised by Cresset Asset Management LLC

Key Points

• Cresset Asset Management LLC increased its stake in IQVIA Holdings Inc. by 8.3%, now holding 53,722 shares valued at approximately $9.47 million.
• IQVIA reported $2.81 earnings per share for the last quarter, exceeding analysts' expectations and showing a year-over-year revenue increase of 5.3% to $4.02 billion.
• Several analysts have raised their price targets for IQVIA, with a consensus average target price of $228.62 and a majority rating the stock as a "Moderate Buy."

Cresset Asset Management LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 53,722 shares of the medical research company's stock after buying an additional 4,097 shares during the period. Cresset Asset Management LLC's holdings in IQVIA were worth $9,471,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Continuum Advisory LLC lifted its position in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares in the last quarter. Ballentine Partners LLC increased its holdings in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after purchasing an additional 69 shares during the last quarter. Independent Advisor Alliance increased its holdings in IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after purchasing an additional 72 shares during the last quarter. ST Germain D J Co. Inc. increased its holdings in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Finally, Nemes Rush Group LLC increased its holdings in IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after purchasing an additional 81 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE:IQV traded up $5.5970 on Friday, hitting $190.9870. The company's stock had a trading volume of 1,619,418 shares, compared to its average volume of 1,441,272. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a market capitalization of $32.47 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30. The stock's 50-day moving average is $173.70 and its two-hundred day moving average is $168.51. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the prior year, the business posted $2.64 earnings per share. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. Robert W. Baird boosted their price target on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Cowen reiterated a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Mizuho boosted their price target on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Finally, Redburn Partners set a $188.00 price target on IQVIA in a report on Friday, May 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.